Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disorder characterized by insulin resistance and gradual decline in pancreatic β-cell function, resulting in persistent hyperglycaemia. The primary objective of treatment is to achieve and maintain optimal glycaemic control while preventing acute and chronic complications. Management begins with lifestyle modification and progresses to oral hypoglycaemic agents and insulin therapy when glycaemic targets are not achieved. Treatment should be individualized according to the patient's age, duration of diabetes, comorbidities, cardiovascular and renal status, risk of hypoglycaemia, and treatment preferences.

Goals of glycaemic management

The objectives of treatment are to achieve optimal metabolic control, reduce symptoms of hyperglycaemia, prevent acute metabolic complications, and minimize long-term microvascular and macrovascular complications.

Recommended treatment targets include:

Principles of treatment

Management should always begin with lifestyle modification and continue throughout the course of the disease, irrespective of pharmacological treatment. Medicines should be intensified promptly when glycaemic targets are not achieved. Patients with severe hyperglycaemia, marked symptoms, serious infection, acute illness, or hyperglycaemic emergencies require immediate assessment for insulin therapy rather than prolonged lifestyle or oral therapy alone.

Glycaemic management algorithm for type 2 diabetes mellitus

Step 1 – Lifestyle modification

Initiate for all patients:

• Healthy diet

• Regular physical activity

• Weight reduction if overweight or obese

• Smoking cessation

• Reduction or avoidance of alcohol

Reassess after approximately 3 months.

If glycaemic targets are achieved:

→ Continue lifestyle modification and routine monitoring.

If glycaemic targets are not achieved:

→ Proceed to oral monotherapy.

Patients presenting with severe hyperglycaemia, marked symptoms, acute illness, serious infection, or hyperglycaemic emergencies should be admitted when appropriate and considered for immediate insulin therapy.

Step 2 – Oral monotherapy

Preferred first-line medicine

Metformin

• Initial dose: 500 mg orally every 12 hours with or after meals

• Increase gradually according to glycaemic response

• Maximum dose: 2,000 mg/day in two or three divided doses

If metformin is contraindicated, prescribe one sulphonylurea:

Glibenclamide

• 2.5–10 mg orally every 12 hours

OR

Glimepiride

• 1–4 mg orally every 12 hours

OR

Gliclazide

• 40–160 mg orally every 12 hours

Treatment should begin with the lowest effective dose and be titrated gradually.

If glycaemic targets are achieved:

→ Continue treatment and routine monitoring.

If glycaemic targets are not achieved:

→ Proceed to combination therapy.

Step 3 – Oral combination therapy

Continue metformin and add one sulphonylurea, or continue the existing sulphonylurea and add metformin where appropriate.

Recommended combinations:

• Metformin + glibenclamide

• Metformin + glimepiride

• Metformin + gliclazide

The additional medicine should be started at the lowest dose and increased gradually according to glycaemic response.

Lifestyle modification should continue.

If glycaemic targets are achieved:

→ Continue combination therapy.

If glycaemic targets are not achieved:

→ Proceed to insulin therapy.

Step 4 – Oral therapy plus insulin

Continue oral hypoglycaemic therapy and initiate bedtime intermediate-acting (NPH) insulin.

Monitor closely while titrating insulin according to blood glucose levels.

Reassess after approximately 3 months.

If glycaemic targets are achieved:

→ Continue the current regimen.

If glycaemic targets are not achieved:

→ Refer for intensive insulin therapy.

Step 5 – Intensive insulin therapy

Patients whose diabetes remains inadequately controlled despite oral therapy and bedtime insulin should be referred to a secondary or tertiary healthcare facility.

Management may include:

• Multiple daily insulin injections (basal-bolus regimen)

• Premixed insulin regimens

• Intensive insulin titration

• Specialist endocrinology assessment

• Evaluation for poor adherence, secondary causes of hyperglycaemia, and diabetes complications

Lifestyle modification

Lifestyle intervention is the foundation of treatment and should continue throughout life.

Dietary management

Objectives include:

• Achieving and maintaining a healthy body weight

• Improving glycaemic control

• Preventing hypo- and hyperglycaemia

• Reducing cardiovascular risk

Recommendations include:

• Consume vegetables, fruits, legumes, whole grains, lean proteins, and low-fat dairy products.

• Carbohydrates should provide approximately 45–60% of daily calories, preferably from complex carbohydrates.

• Protein should provide approximately 15–20% of daily energy intake (about 1 g/kg/day).

• Fat should contribute less than 30% of daily calories and less than 20% in obese individuals.

• Avoid sugar-sweetened beverages, simple sugars, and honey.

• Eat three balanced meals daily with healthy snacks when appropriate.

• Limit salt intake to less than one teaspoon daily.

Physical activity

• At least 150 minutes of moderate-intensity exercise each week.

• Include both aerobic and resistance exercises.

• Adjust medication doses or carbohydrate intake to reduce the risk of exercise-induced hypoglycaemia.

Smoking

Complete smoking cessation is recommended.

Alcohol

• Women: not more than one standard drink daily.

• Men: not more than two standard drinks daily.

Impaired glucose tolerance

Individuals with impaired glucose tolerance have an increased risk of developing type 2 diabetes mellitus.

Progression may be delayed by:

• Dietary modification

• Regular physical activity

• Weight reduction

• Metformin therapy in selected high-risk individuals

Monitoring during treatment

Patients should be reviewed regularly to assess:

• Symptoms of hypo- or hyperglycaemia

• Weight

• Blood pressure

• Medication adherence

• Lifestyle adherence

• Development of complications

Routine laboratory monitoring should include:

• Fasting blood glucose

• HbA1c every three months until stable, then at least every six months

• Renal function

• Lipid profile

• Urine albumin

• Other investigations as clinically indicated

Treatment failure

Treatment should be reviewed and intensified if:

• HbA1c remains above target despite good adherence

• Fasting blood glucose remains persistently elevated

• Recurrent hypoglycaemia develops

• Significant adverse drug reactions occur

• Progressive weight loss develops

• Symptoms of insulin deficiency appear

The maximum glucose-lowering effect of oral hypoglycaemic agents is generally evident within six months. Failure to achieve glycaemic targets after adequate dose titration should prompt treatment intensification rather than prolonged continuation of ineffective therapy.

Patient education

Patients should receive ongoing education regarding:

• The nature of diabetes

• Healthy eating

• Physical activity

• Medication adherence

• Recognition and management of hypoglycaemia

• Recognition of hyperglycaemia

• Foot care

• Sick-day management

• Smoking cessation

• Alcohol moderation

• Importance of regular clinic attendance

Clinical pearls

• Lifestyle modification should continue throughout all stages of treatment.

• Metformin remains the preferred first-line oral agent unless contraindicated.

• Sulphonylureas should be initiated at the lowest effective dose and titrated gradually.

• Patients presenting with severe hyperglycaemia, acute illness, serious infection, or hyperglycaemic emergencies should be evaluated promptly for insulin therapy.

• Failure of monotherapy should prompt combination therapy rather than substitution with another single oral agent.

• Failure of maximum tolerated combination therapy should prompt timely initiation of insulin.

• Glycaemic control should be assessed regularly using fasting blood glucose and HbA1c, with treatment intensified whenever therapeutic targets are not achieved.

This version removes the duplicated "Step 2–5" sections that appeared twice in your draft, consolidates the algorithm into a single section, and places the detailed lifestyle, monitoring, and education sections after the treatment algorithm, resulting in a cleaner textbook-style chapter.